CeQur has secured USD 115 million in funding to advance its commercial plans for the CeQur Simplicity insulin patch, aimed at revolutionizing diabetes management.

Information on the Target

CeQur has successfully completed its funding round, raising a total of USD 115 million to advance its commercial plans for the CeQur Simplicity device. CeQur Simplicity is a user-friendly, discreet insulin patch designed for three-day wear, allowing for injection-free dosing. This innovative product ensures that insulin is always within reach for diabetic patients. The commercial plans involve market development activities and a phased market entry strategy, aiming for a 2021 product launch, alongside the establishment of large-scale production capabilities.

CeQur specializes in advanced insulin delivery devices that enable diabetics to adhere to their therapy effectively and manage their condition control. The company's three-day wearable insulin patches provide a new level of freedom for diabetics in their daily lives.

Industry Overview in the Target’s Specific Country

In the United States, the diabetes management industry is witnessing significant growth, driven by the increasing prevalence of diabetes among the population. According to the Center